- Home
- GPRE vs XOMAP Comparison
GPRE vs XOMAP Comparison
Compare GPRE & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- XOMAP
- Stock Information
- Founded
- GPRE 2004
- XOMAP N/A
- Country
- GPRE United States
- XOMAP United States
- Employees
- GPRE N/A
- XOMAP 13
- Industry
- GPRE Major Chemicals
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- GPRE Industrials
- XOMAP Health Care
- Exchange
- GPRE Nasdaq
- XOMAP Nasdaq
- Market Cap
- GPRE N/A
- XOMAP N/A
- IPO Year
- GPRE N/A
- XOMAP N/A
- Fundamental
- Price
- GPRE $4.83
- XOMAP $25.93
- Analyst Decision
- GPRE Buy
- XOMAP
- Analyst Count
- GPRE 9
- XOMAP 0
- Target Price
- GPRE $18.63
- XOMAP N/A
- AVG Volume (30 Days)
- GPRE 2.4M
- XOMAP N/A
- Earning Date
- GPRE 05-02-2025
- XOMAP N/A
- Dividend Yield
- GPRE N/A
- XOMAP N/A
- EPS Growth
- GPRE N/A
- XOMAP N/A
- EPS
- GPRE N/A
- XOMAP N/A
- Revenue
- GPRE $2,458,796,000.00
- XOMAP N/A
- Revenue This Year
- GPRE $4.52
- XOMAP N/A
- Revenue Next Year
- GPRE $3.00
- XOMAP N/A
- P/E Ratio
- GPRE N/A
- XOMAP N/A
- Revenue Growth
- GPRE N/A
- XOMAP N/A
- 52 Week Low
- GPRE $4.62
- XOMAP N/A
- 52 Week High
- GPRE $24.04
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- GPRE 34.24
- XOMAP 58.85
- Support Level
- GPRE $4.98
- XOMAP $25.73
- Resistance Level
- GPRE $5.54
- XOMAP $25.93
- Average True Range (ATR)
- GPRE 0.36
- XOMAP 0.09
- MACD
- GPRE 0.05
- XOMAP 0.03
- Stochastic Oscillator
- GPRE 4.67
- XOMAP 93.11
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.